US Stock MarketDetailed Quotes
SNGX Soligenix
- 3.8000
- -0.1700-4.28%
Close Oct 1 16:00 ET
8.67MMarket Cap-475P/E (TTM)
3.9900High3.7500Low46.59KVolume3.9900Open3.9700Pre Close178.10KTurnover2.05%Turnover RatioLossP/E (Static)2.28MShares32.000052wk High2.50P/B8.66MFloat Cap1.830152wk Low--Dividend TTM2.28MShs Float719999.6400Historical High--Div YieldTTM6.05%Amplitude1.8300Historical Low3.8220Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Soligenix Stock Forum
Soligenix Will Be Issued U.S. Patent Number 12,097,291 Tomorrow Titled "Thermostable Vaccine Compositions And Methods Of Preparing Same"
$Soligenix (SNGX.US)$
$SciSparc (SPRC.US)$
$Bitcoin (BTC.CC)$
$Bitcoin (BTC.CC)$
$SciSparc (SPRC.US)$
$Soligenix (SNGX.US)$
Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, has been making progress in the treatment of Cutaneous T-Cell Lymphoma (CTCL) with its investigational drug, HyBryte™. In an exclusive interview with PCG Digital, Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigato...
📊⚡️📊
Larger Image: tradingview.com...
$Soligenix (SNGX.US)$
No comment yet